/VERV
VERV Stock - Verve Therapeutics, Inc.
Healthcare|BiotechnologyNASDAQ
$11.13+0.27%
+$0.03 (+0.27%) • Jul 25
76
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.100
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.31
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+34.8%upside
Target: $15.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for VERV
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$11.02 – $11.24
TARGET (TP)$15.00
STOP LOSS$10.24
RISK/REWARD1:4.3
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta2.24
52W High$11.40
52W Low$2.87
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $32.33M | $11.76M | $1.94M | N/A | N/A |
| Gross Profit | $32.33M | $11.76M | $1.94M | $-3,377,000 | $-1,328,000 |
| Gross Margin | 100.0% | 100.0% | 100.0% | N/A | N/A |
| Operating Income | $-228,660,000 | $-223,124,000 | $-165,687,000 | $-87,067,000 | $-40,627,000 |
| Net Income | $-198,709,000 | $-200,068,000 | $-157,387,000 | $-118,637,000 | $-45,542,000 |
| Net Margin | -614.6% | -1701.5% | -8108.6% | N/A | N/A |
| EPS | $-2.36 | $-3.12 | $-2.91 | $-2.45 | $-0.94 |
Company Overview
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with Beam Therapeutics Inc.; a development and option agreement with Acuitas Therapeutics, Inc.; and a Cas9 license agreement with The Broad Institute and the President and Fellows of Harvard College. The company was formerly known as Endcadia, Inc. and changed its name to Verve Therapeutics, Inc. in January 2019. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
4
57%
Hold / Neutral
2
29%
Sell / Underperform
1
14%
Analyst Consensus🟡 Mixed
4 Bullish3 Neutral/Bearish
Price Targets
$33
Average Target
↑ 195.2% Upside
Now
$13
Low
$33
Average
$56
High
Based on 7 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| April 15th 2025 | Cantor Fitzgerald | Upgrade | Overweight | - |
| April 8th 2024 | H.C. Wainwright | Initiation | Buy | $15 |
| April 13th 2023 | Canaccord Genuity | Initiation | Buy | $29 |
| February 1st 2023 | Cantor Fitzgerald | Initiation | Neutral | $21 |
| December 15th 2022 | Goldman | Initiation | Sell | $13 |
| October 6th 2022 | Credit Suisse | Initiation | Neutral | $48 |
| August 25th 2022 | Stifel | Upgrade | Buy | $56← $32 |
| June 17th 2022 | BMO Capital Markets | Initiation | Outperform | $48 |
Earnings History & Surprises
VERVBeat Rate
65%
Last 17 quarters
Avg Surprise
-67.6%
EPS vs Estimate
Beats / Misses
11/6
Last 12 quarters
Latest EPS
$-0.59
Q3 2025
EPS Surprise History
Q4 23
+20.9%
$-0.72vs$-0.91
Q1 24
+13.8%
$-0.69vs$-0.80
Q2 24
+13.2%
$-0.59vs$-0.68
Q3 24
+13.2%
$-0.59vs$-0.68
Q4 24
+15.7%
$-0.59vs$-0.70
Q1 25
+19.4%
$-0.58vs$-0.72
Q2 25
+50.7%
$-0.35vs$-0.71
Q3 25
+15.7%
$-0.59vs$-0.70
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 14, 2025 | $-0.70 | $-0.59 | +15.7% | ✓ BEAT |
Q2 2025 | May 14, 2025 | $-0.71 | $-0.35 | +50.7% | ✓ BEAT |
Q1 2025 | Feb 27, 2025 | $-0.72 | $-0.58 | +19.4% | ✓ BEAT |
Q4 2024 | Nov 5, 2024 | $-0.70 | $-0.59 | +15.7% | ✓ BEAT |
Q3 2024 | Aug 8, 2024 | $-0.68 | $-0.59 | +13.2% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-0.68 | $-0.59 | +13.2% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $-0.80 | $-0.69 | +13.8% | ✓ BEAT |
Q4 2023 | Nov 7, 2023 | $-0.91 | $-0.72 | +20.9% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.91 | $-0.87 | +4.4% | ✓ BEAT |
Q2 2023 | May 15, 2023 | $-0.78 | $-0.84 | -7.7% | ✗ MISS |
Q1 2023 | Mar 2, 2023 | $-0.76 | $-0.67 | +11.8% | ✓ BEAT |
Q4 2022 | Nov 7, 2022 | $-0.75 | $-0.79 | -5.3% | ✗ MISS |
Q3 2022 | Aug 9, 2022 | $-0.63 | $-0.84 | -33.3% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-0.63 | $-0.62 | +1.6% | ✓ BEAT |
Q1 2022 | Mar 14, 2022 | $-0.54 | $-0.65 | -20.4% | ✗ MISS |
Q4 2021 | Nov 10, 2021 | $-0.45 | $-0.47 | -4.4% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-0.49 | $-6.66 | -1259.2% | ✗ MISS |
Q2 2021 | Jun 17, 2021 | — | $-0.81 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.30 | — | — |
Q3 2020 | Sep 30, 2020 | — | $-0.31 | — | — |
Latest News
Eli Lilly to acquire for Verve Therapeutics for up to $1.3B
📈 PositiveSeeking Alpha•Jun 17, 2025, 10:54 AM•Also:
Eli Lilly nears $1.3B deal for Verve Therapeutics - report
📈 PositiveSeeking Alpha•Jun 17, 2025, 08:09 AM•Also:
Verve extends gains as Cantor Fitzgerald upgrades on data for cholesterol drug
📈 PositiveSeeking Alpha•Apr 15, 2025, 02:38 PM
Verve jumps after early-stage trial data for gene editing therapy
📈 PositiveSeeking Alpha•Apr 14, 2025, 12:29 PM•Also:
Frequently Asked Questions about VERV
What is VERV's current stock price?
Verve Therapeutics, Inc. (VERV) is currently trading at $11.13 per share. The stock has moved +0.27% today.
What is the analyst price target for VERV?
The average analyst price target for VERV is $15.00, based on 1 analyst.
What sector is Verve Therapeutics, Inc. in?
Verve Therapeutics, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is VERV's market cap?
Verve Therapeutics, Inc. has a market capitalization of $0.99 billion, making it a small-cap company.
Does VERV pay dividends?
No, Verve Therapeutics, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorALBO
Albireo Pharma, Inc.
$44.15
Mkt Cap: $0.9B
CBIO
Crescent Biopharma, Inc.
$11.85
Mkt Cap: $0.2B
CDMO
Avid Bioservices, Inc.
$12.49
Mkt Cap: $0.8B
EQRX
EQRx, Inc.
$2.34
Mkt Cap: $1.1B
ETHZ
Ethzilla Corp.
$6.90
Mkt Cap: $0.1B
GRCL
Gracell Biotechnologies Inc.
$10.25
Mkt Cap: $0.2B
HARP
Harpoon Therapeutics, Inc.
$23.01
Mkt Cap: $0.9B
PSTX
Poseida Therapeutics, Inc.
$9.50
Mkt Cap: $0.9B
VECT
VectivBio Holding AG
$16.87
Mkt Cap: $1.1B
Explore stocks similar to VERV for comparison